Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
2.230
+0.020 (0.91%)
Dec 20, 2024, 4:00 PM EST - Market closed
Lexaria Bioscience Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lexaria Bioscience stock have an average target of 11, with a low estimate of 10 and a high estimate of 12. The average target predicts an increase of 393.27% from the current stock price of 2.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LEXX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +348.43% | Dec 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +348.43% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +348.43% | Jul 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +348.43% | Jul 10, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $3 → $12 | Strong Buy | Maintains | $3 → $12 | +438.12% | Mar 5, 2024 |
Financial Forecast
Revenue This Year
558.96K
from 464.28K
Increased by 20.39%
Revenue Next Year
1.19M
from 558.96K
Increased by 113.25%
EPS This Year
-0.45
from -0.47
EPS Next Year
-0.48
from -0.45
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 730,800 | 1.2M | 3.7M | ||
| Avg | 558,960 | 1.2M | 3.6M | ||
| Low | 392,000 | 1.1M | 3.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 57.4% | 119.5% | 209.9% | ||
| Avg | 20.4% | 113.3% | 201.0% | ||
| Low | -15.6% | 105.0% | 189.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.39 | -0.36 | -0.90 |
| Avg | -0.45 | -0.48 | -0.88 |
| Low | -0.47 | -0.59 | -0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.